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TIMP-1Is SignificantlyAssociated with Objective Response and
Survival in Metastatic Colorectal Cancer Patients Receiving
Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid
NannaM. Srensen,1Per Bystro« m,2 IbJ. Christensen,3 A˚ke Berglund,4 HansJrgen Nielsen,3
Nils Bru« nner,1and Bengt Glimelius2,4
Abstract Purpose: Tissue inhibitor of metalloproteinase-1 (TIMP-1) is known to protect cells against
apoptosis.We raised the hypothesis that elevated tumor tissue levels and thereby plasma levels
of TIMP-1would predict resistance to apoptosis-inducing chemotherapy.
Experimental Design: Ninety patients with metastatic colorectal cancer were included in the
study. PlasmaTIMP-1and serum carcinoembryonic antigen (CEA) were measured in samples
obtained before the first cycle of chemotherapy.
Results: Analysis of best objective response (complete or partial response versus stable or
progressive disease) showed that patients with low plasmaTIMP-1had higher probability of
obtaining an objective response [odds ratio (OR), 3.5; 95% confidence interval (95% CI),
1.4-8.5,P =0.007].CEA treatedas a continuous variablewas also a statistically significantpredic-
torof no response (OR,1.3; 95%CI,1.0-1.7,P =0.02, areaunder the curve 0.66) butmuch less so.
PlasmaTIMP-1was the only significant covariate in a multivariable analysis of best objective
response (OR, 3.6; 95%CI,1.4-9.5; P = 0.001). PlasmaTIMP-1scored as a continuous variable on
the log scale (loge) was significantly associated with overall survival [OS; hazard ratio (HR), 3.8;
95% CI, 2.4-5.9; P < 0.0001] and with time to progression (TTP; HR, 1.5; 95% CI, 1.0-2.3; P =
0.048). Multivariable analysis showed that plasmaTIMP-1was significant for OSwhen including
routine clinical baseline covariates (HR, 3.5; 95%CI, 2.1-5.8; P < 0.0001). Amultivariable analysis
includingTTP instead of OS showed that only plasmaTIMP-1was retained in the model (HR,1.5).
CEA was not significantly associated withTTP or OS whenTIMP-1was included in the model.
Conclusion: This study shows that plasmaTIMP-1 levels are significantly and independently
associated with objective response,TTP, and OS in patients with metastatic colorectal cancer
receiving combination chemotherapy.
In Europe and the United States, the number of new colorectal
cancer cases approximates 500,000 on a yearly basis.5 Approxi-
mately half of the patients will develop metastatic colorectal
cancer disease, and these patients are candidates for systemic
chemotherapy. However, the objective response rate [complete
response (CR) and partial response (PR)] is onlyf50%, which
means that half of the patients will receive treatment with no
substantial clinical benefit.
Today, there is no single biomarker that can be used to
predict response/resistance to chemotherapy in metastatic
colorectal cancer patients (1). As most types of conventional
chemotherapy kill cancer cells by inducing apoptosis, it could
be hypothesized that markers of apoptosis protection would be
useful as markers of chemotherapy resistance.
The proteinases inhibitor, tissue inhibitor of metalloprotei-
nase-1 (TIMP-1), inhibits, in addition to its matrix metal-
loproteinase inhibitory function, apoptosis (2–5).
We and others have shown that plasma levels of TIMP-1
in patients with primary colorectal cancer are associated with
patient outcome; that is, high plasma TIMP-1 predicts shorter
patient survival (6–12). One explanation to this association is
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that TIMP-1 protects cancer cells against the apoptotic stimuli
that constitutively affect the cells. In support of an antiapoptotic
function of TIMP-1, we have recently shown that in a cohort
of 173 patients with metastatic breast cancer, high tumor
tissue levels of TIMP-1 were highly significantly associated with
chemotherapy resistance (13). For example, in patients with
high tumor tissue TIMP-1 levels, the objective response (CR
and PR) to chemotherapy was 0%. In accordance with these
findings, Lipton et al. (14) showed that high plasma TIMP-1
was significantly associated with resistance to the antiestrogen
tamoxifen in patients with metastatic breast cancer.
Based on the current knowledge of TIMP-1 as a protector of
cancer cell apoptosis, we raised the hypothesis that levels of
plasma TIMP-1 in patients with metastatic colorectal cancer
would be predictive of response to chemotherapy. Indeed, the
present study, including a homogeneous group of previously
untreated patients treated with combination chemotherapy
within a prospective trial, supports our hypothesis because a
highly significant correlation was found between these two
variables.
Patients andMethods
Patients and treatment. The study included 90 patients diagnosed
with metastatic colorectal cancer. The study was done on a
subpopulation of a larger study, NORDIC VI, a randomized phase III
Nordic multicenter trial with 567 included patients comparing
irinotecan in combination with either the Nordic bolus 5-fluorouracil
(5-FU) and folinic acid schedule or the bolus/infused de Gramont
schedule, in patients with metastatic colorectal cancer. All patients in
two of the centers, Karolinska University Hospital (Stockholm,
Sweden) and Akademiska Hospital (Uppsala, Sweden), were consecu-
tively asked if they accepted the additional blood samples required in
the study. In these two centers, 122 patients were randomized to the
main study and 90 accepted the extra investigations on the blood
samples. Of these, 87 were evaluable for objective response to
chemotherapy.
Of the 90 patients, 77 had liver metastases, 23 lung metastases,
9 lymph node metastases, and 11 patients had multiple metastases.
Eligibility criteria included histologically proven adenocarcinoma of
colon or rectum with metastatic disease, age between 18 and 75 years,
no prior chemotherapy or only adjuvant chemotherapy if terminated
>6 months before randomization was accepted, performance status
(WHO) of 0 to 2, and at least one measurable metastatic lesion
according to the Response Evaluation Criteria in Solid Tumors (15).
Written informed consent was obtained for all patients. Exclusion
criteria included central nervous system metastases, current infection,
diabetes, unresolved bowel obstruction, uncontrolled inflammatory
bowel disease, current history of chronic diarrhea, or any other serious
medical condition.
According to the study protocol, patients were randomized to receive
either of the following treatments:
Arm A. Irinotecan: 180 mg/m2 as a 30 to 90 min i.v. infusion on day
1 every 2 weeks immediately followed by 5-FU: 500 mg/m2 i.v. bolus
on days 1 and 2 every 2 weeks, followed 30 to 40 min later by folinic
acid: 60 mg/m2 i.v. bolus on days 1 and 2 every 2 weeks.
Arm B. Irinotecan: 180 mg/m2 as a 30 to 90 min. i.v. infusion day 1
every 2 weeks, followed by folinic acid: 200 mg/m2 as a 2 h i.v.
infusion, days 1 and 2 every 2 weeks, followed by 5-FU: 400 mg/m2
i.v. bolus followed by 600 mg/m2 5-FU as a 22 h i.v. infusion days 1
and 2 every 2 weeks.
Response evaluation. The primary efficacy variable was TTP defined
as the time from randomization to the first documented progression or
death due to progression. The secondary efficacy variable was overall
survival (OS) calculated from the date of randomization until death.
Responses were evaluated after every fourth cycle or every 2nd month if
treatment was terminated. Treatment continued until progression or
severe toxicity was noted. Overall response rate was defined as CR and
PR as it is defined according to the Response Evaluation Criteria in
Solid Tumors (15).
TIMP-1 analyses. EDTA plasma samples were drawn before start of
chemotherapy. The samples were stored at -80jC until analyzed. In
addition, in 75 of the patients, plasma samples were collected at 2, 4,
and 6 weeks of treatment (samples were drawn before the initiation of
each cycle). As previously described, plasma levels of TIMP-1 were
determined by use of an established, validated TIMP-1 ELISA (6). In
brief, for measurements of TIMP-1 protein levels, microtiter plates were
coated with a sheep polyclonal antibody and detection of bound TIMP-
1 (free and complex-bound forms) was done by use of a monoclonal
antibody (MAC 15) and a secondary alkaline phosphatase–coupled
antibody (DAKO). Readings of color development were taken every
10 min for 1 h, and calculations of concentrations were based on
included recombinant TIMP-1 protein standards.
Carcinoembryonic antigen analyses. Serum samples were drawn
before start of chemotherapy and after 2, 4, and 8 to 10 weeks of
treatment. The level of carcinoembryonic antigen (CEA) was measured
using the immunometric assay from DiaSorin.
Statistics. Descriptive statistics are presented by the median and
range. Tests for location were done using the Wilcoxon rank sum test or
the Kruskal-Wallis test and the Spearman rank correlation was used as a
measure of association. Covariates are either dichotomized by their
median or entered by the actual value on the log scale (natural).
Survival probabilities for time to progression (TTP) and OS are
estimated by the Kaplan-Meier method and tests for differences between
strata are done using the log-rank statistics. Analyses of TTP and OS for
continuous covariates as well as multivariate analyses are done using
the Cox proportional hazards model. The estimation of the probability
of response is done using logistic regression analysis and results are
presented using the odds ratio (OR) and the receiver operating
characteristic curve, including the area under the curve. P values <5%
are considered statistically significant. All calculations are done using
SAS (version 9.1, SAS Institute).
Results
Levels of plasma TIMP-1 and association with baseline
variables. All plasma samples contained measurable levels of
TIMP-1. The median concentration was 121.9 ng/mL (range,
20.2-1,001.4 ng/mL) of plasma. The 95 percentile was 169.2
ng/mL of TIMP-1. Associations between plasma TIMP-1
and baseline variables are given in Table 1. Plasma TIMP-1
values were significantly associated with performance status
(P = 0.003). In addition, TIMP-1 marginally associated with
adjuvant treatment (P = 0.049); high TIMP-1 levels were found
in those patients who had not received adjuvant treatment. No
significant associations were seen between plasma TIMP-1
and age (r = 0.16, P = 0.12), gender (P = 0.36), location of
the cancer (colon or rectum; P = 0.69), or allocated treatment
(P = 0.92).
Levels of plasma TIMP-1 and serum CEA and association with
best objective response. Eighty-seven patients were evaluable for
response. Analysis of best objective response was scored as CR
or PR versus stable disease (SD) or progressive disease (PD).
Four patients obtained CR, 36 PR, 38 SD, and 9 PD. Of the
38 SD patients, eight had duration of SD <4 months. When
TIMP-1 was treated as a continuous variable, the univariable
analyses showed that patients with high plasma TIMP-1 had
higher probability of no response [SD or PD; OR, 3.5; 95%
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confidence interval, (95% CI), 1.4-8.5; P = 0.007]. The area
under the curve was 0.67. Using the median TIMP-1 levels to
dichotomize the patients showed that among the 44 patients
with low TIMP-1, 26 (59%; 95% CI, 44-74%) obtained CR
or PR, whereas among the 43 patients with high plasma
TIMP-1, only 14 (33%; 95% CI, 19-47%) obtained an objective
response. Stratifying patients with SD by duration of response
showed that among the eight patients with SD <4 months,
seven (88%) had plasma TIMP-1 levels above the median.
Plasma TIMP-1 scored as a continuous covariate on the log
scale entered into a multivariate logistic regression analysis
showed that only TIMP-1 was a significant predictor of no
response (SD and PD; OR, 3.6; 95% CI, 1.4-9.5; P = 0.001;
Table 2). The OR for a patient with TIMP-1 level equal to the
3rd quartile of TIMP-1 levels compared with one with TIMP-1
equal to the 1st quartile was 2.4 (95% CI, 1.2-4.6).
Serum CEA levels were available for 67 of the 87 patients.
The median CEA level was 56 units/mL, ranging from 1 to
4,073. The rank correlation between CEA and TIMP-1 was 0.31
(P = 0.01). This subset of patients is similar to the entire data
set with respect to the distribution of the clinical covariates, age,
and TIMP-1 levels. CEA treated as a continuous variable was a
significant predictor of no response (OR, 1.3; 95% CI, 1.0-1.7;
P = 0.02; area under the curve 0.66). Combining CEA with
TIMP-1 did not result in a significantly improved fit; the P value
to include CEA in a model with TIMP-1 was 0.09.
Levels of plasma TIMP-1 and serum CEA and association with
TTP and OS. Ninety patients were evaluable for TTP and OS.
There was a significant trend between TTP [hazard ratio (HR),
1.5; 95% CI, 1.0-2.3, P = 0.048] and plasma TIMP-1 scored as a
continuous variable on the log scale (loge). Kaplan-Meier
estimates of TTP are shown in Fig. 1 with TIMP-1 dichotomized
by the median. The figure illustrates that patients with plasma
TIMP-1 levels below the median have a significantly longer TTP
(HR, 1.9; 95% CI, 1.2-3.0; P = 0.01) than patients with plasma
TIMP-1 above the median. The results of a multivariate analysis
including TIMP-1 and TTP are shown in Table 3. TIMP-1 is not
significant at the 5% level (P = 0.06); however, TIMP-1 is the
only covariate close to statistical significance and model
selection results in TIMP-1 being the only covariate showing
statistical significance.
When testing for an association between plasma TIMP-1
scored as a continuous variable on the log scale (loge) and OS, a
significant association between these two variables was found
(HR, 3.8; 95% CI, 2.4-5.9; P < 0.0001). Kaplan-Meier estimates
of OS dichotomizing plasma TIMP-1 by its median level are
shown in Fig. 2. As seen from this figure, there was a highly
statistically significant difference in OS between patients with
low versus high plasma TIMP-1 levels (HR, 4; 95% CI, 2.2-7.3;
P < 0.0001). At time point 24 months, 16 patients were still
at risk in the low TIMP-1 group whereas only two patients were
at risk in the high TIMP-1 group. The survival probability at 24
months was 62% (95% CI, 46-77%) for patients with plasma
TIMP-1 below the median level and 7% (95% CI, 0-17%) for
those with TIMP-1 levels above the median. Multivariate
analysis showed (Table 4) that plasma TIMP-1 was significant
Table 2. Multivariate logistic regression analysis
of no response (SD and PD) to chemotherapy
Covariate P OR (95% CI)
Randomized to
FLIRI 0.54 1.3 (0.5-3.5)
FOLFIRI
Gender
Male 0.52 1.4 (0.5-3.7)
Female
Localization
Colon 0.76 1.6 (0.6-4.2)
Rectum
Performance status WHO
0 0.81 0.9 (0.3-2.8)
1 + 2
Adjuvant therapy
No 0.84 0.9 (0.2-3.4)
Yes
Age (y) 0.60 1.01 (0.96-1.07)
TIMP-1 loge 0.001 3.6 (1.4-9.5)
Table 1. Associations between plasma TIMP-1 and
baseline covariates
Covariate N = 90 Association to
TIMP-1 P
Randomized to
FLIRI 44 0.92
FOLFIRI 46
Gender
Male 60 0.36
Female 30
Localization
Colon 59 0.69
Rectum 31
Performance status WHO
0 69 0.003
1 17
2 4
Adjuvant therapy
No 79 0.049
Yes 11
Age median (min, max; y) 60 (36-75) 0.16*
Abbreviations: FLRI, Nordic bolus 5-FU and folinic acid schedule;
FOLFIRI, bolus/infused de Gramont schedule.
*Spearman rank correlation (P = 0.12).
Fig. 1. Kaplan-Meier curves showing the association between plasmaTIMP-1
values andTTP.The number of events (progressions) and number of patients at risk
at different time points during the observation period for each of the two groups
are given below the figure. Solid line, patients with plasmaTIMP-1levels below the
median; broken line, patients with plasmaTIMP-1levels above the median.
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www.aacrjournals.org Clin Cancer Res 2007;13(14) July15, 20074119
for OS when including routine clinical baseline covariates
(HR, 3.5; 95% CI, 2.1-5.8; P < 0.0001). The only other
significant covariate for OS was performance score (HR, 2.4;
95% CI, 1.2-4.5; P = 0.008). In a multivariable analysis now
including TTP instead of OS, plasma TIMP-1 and baseline
covariates showed that only plasma log TIMP-1 treated as a
continuous variable was retained in the model (HR, 1.5; 95%
CI,1.0-2.3; P = 0.049).
Assessment of CEA used as a continuous variable on the log
scale for the analysis of TTP and OS showed that this model
formulation was inappropriate (not linear on a log scale). CEA
was not a significant predictor of TTP (n = 68, P = 0.56) using
the conventional cutpoint of 5 units/mL. Nor was CEA a
significant predictor of OS (P = 0.56) in a model also including
TIMP-1.
Discussion
The present study shows that high plasma levels of TIMP-1 in
patients with metastatic colorectal cancer treated with first-line
combination chemotherapy are indicative of low probability of
objective response to chemotherapy. This decreased probability
of obtaining an objective response to chemotherapy in plasma
high TIMP-1 patients was reflected in a significantly decreased
TTP and OS of these patients. Based on the present results, it is,
however, not possible to clearly separate the effect of TIMP-1 on
prognosis (6–12) or on objective response to chemotherapy.
The possibility to predict response to chemotherapy in
metastatic colorectal cancer has wide implications as it is
anticipated that presently only f50% of metastatic colorectal
cancer patients receiving chemotherapy have clear benefit
thereof. A predictive biomarker could thus be used to protect
patients from ineffective treatment and thereby from the
adverse effects induced by chemotherapy. On the other hand,
the predictive biomarker could be used to select metastatic
colorectal cancer patients not only for routine systemic
chemotherapy, but also for clinical trials testing either different
or more aggressive treatment schedules, or new types of
chemotherapy/biological–based therapy.
In the present study, the patients received irinotecan and 5-
FU + folinic acid by two different schedules. The treatment
schedule was not retained in the multivariate analysis,
suggesting that the association between plasma TIMP-1 and
objective response was independent of treatment schedule but
directly related to tumor sensitivity/resistance to the drugs.
Analyses of the entire randomized study of 557 patients reveal
that there is no difference between schedules for either TTP or
OS.6 The question then arise whether the present results are
only valid when these two drugs are being used or whether
plasma TIMP-1 would also predict sensitivity/resistance to
other classes of chemotherapeutic compounds. We have
recently found that patients with metastatic breast cancer and
high tumor tissue levels of TIMP-1 in the tumor tissue sampled
at the time of primary surgery are resistant to systemic
chemotherapy, either the combinations of cyclophosphamide,
methotrexate and 5-FU, cyclophosphamide, epirubicin and
5-FU, or doxorubicin given alone (13). Taking these data
together with the present findings suggest that TIMP-1 predicts
for sensitivity/resistance to several classes of chemotherapy.
The strong associations with both TTP, directly related to the
efficacy of the first-line combination, and OS, influenced also
by the efficacy of subsequent lines of treatment, suggest that the
predictive ability is not restricted to the used combination. In
further support of this statement is that in our experimental
model consisting of wild-type and TIMP-1 gene-deficient
fibrosarcoma cells (16), we consistently find the TIMP-1–
expressing wild-type cells more resistant than the TIMP-1 gene-
deficient cells to a variety of chemotherapeutic compounds
(etoposide, vincristine, and Cytosar).
CEA levels were also measured in a subset of the patients
(n = 67). CEA treated as a continuous variable was found to be
significantly associated with objective response, with higher
serum CEA levels predicting lack of objective response.
However, when combining CEA with TIMP-1, no significantly
improved fit was obtained. Serum CEA was neither a significant
predictor of TTP nor of OS when TIMP-1 was included as the
only other covariate.
The antiapoptotic effect of TIMP-1 can be regulated both in a
matrix metalloproteinase (MMP)–dependent and a MMP-
independent way. In vivo and in vitro experiments, using
Fig. 2. Kaplan-Meier curves showing the association between plasma TIMP-1
values and OS.The number of events (disease related deaths) and number of
patients at risk at different time points during the observation period for each of the
two groups are given below the figure. Solid line, patients with plasmaTIMP-1
levels below the median; broken line, patients with plasmaTIMP-1levels above
the median.
6 B. Glimelius et al., unpublished information.
Table 3. Multivariate Cox regression analysis of TTP
Covariate P HR (95% CI)
Randomized to
FLIRI 0.33 1.3 (0.8-2.1)
FOLFIRI
Gender
Male 0.33 0.8 (0.5-1.3)
Female
Localization
Colon 0.20 0.7 (0.4-1.2)
Rectum
Performance status WHO
0 0.68 1.1 (0.6-2.0)
1 + 2
Adjuvant therapy
No 0.54 1.3 (0.6-2.8)
Yes
Age (y) 0.31 1.00 (0.96-1.01)
TIMP-1 loge 0.06 1.5 (1.0-2.3)
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mammary epithelial cells, have shown that apoptotic effector
molecules, such as caspases, are induced by degradation of
the extracellular matrix by MMPs, leading to apoptotic cell
death (2–4). As such, the anti-MMP function of TIMP-1 would
indirectly inhibit apoptosis. In support of this notion is a study
of apoptosis in mammary epithelial cells originating from
MMP-3 transgenic mice showing that the number of apoptotic
cells was significantly reduced when the cells came from
MMP-3 transgenic/TIMP-1–overexpressing mice (4). In sup-
port of an MMP-independent TIMP-1 antiapoptotic function
is that reduced or alkylated TIMP-1, completely devoid of
all MMP inhibitory activity, effectively inhibits apoptosis in
Burkitt’s lymphoma cells (5). In the same study, it was also
reported that addition of recombinant TIMP-1 lead to
inhibition of apoptosis, and that addition of anti–TIMP-1
antibodies to neutralize secreted TIMP-1 resulted in a 4-fold
increase in induction of apoptosis. The antiapoptotic mecha-
nism of TIMP-1 could be mediated by interaction with a
binding protein, which may induce survival signals through
activation of the focal adhesion kinase and/or the phosphati-
dylinositol 3-kinase, leading to increased expression of the
antiapoptotic protein Bcl-XL and preventing activation of the
caspase cascade (17–20). Indeed, it was recently reported that
TIMP-1 binds to CD63, which is a membrane protein
belonging to the family of teraspanin molecules (21). Added
TIMP-1 was shown to bind to cell surfaces, inducing activation
of the above-described signaling pathway leading to protection
of the cells from apoptotic stimuli.
Knowing that TIMP-1 can induce chemoresistance in
cancer cells in vitro, it is obvious to speculate whether
TIMP-1 could represent a valid target for increasing tumor
cell sensitivity to chemotherapy. Normal cells do not over-
express TIMP-1, and the TIMP-1 gene–deficient mouse is
without any detectable phenotype, suggesting that systemic
inhibition of TIMP-1 in a patient, who subsequently receives
chemotherapy, would not induce additional toxicity in the
normal tissue. We have recently published that also another
proteinase inhibitor, plasminogen activator inhibitor-1, pro-
tects cancer cells against apoptosis induced by a wide range
of chemotherapeutic compounds (22, 23). Of particular
interest was that although PAI-1 gene–deficient murine
fibrosarcoma cells showed increased sensitivity to chemo-
therapy in vitro , no difference in systemic toxicity was
observed when exposing PAI-1 gene–deficient and wild-type
mice to chemotherapy.
The present study was done on plasma. We believe that the
elevated plasma TIMP-1 found in the metastatic colorectal
cancer patients originates from the metastatic tumor tissue and
thereby reflects production and secretion of TIMP-1 from the
tumor tissue. It could thus be of interest to test whether tumor
tissue TIMP-1 instead of plasma TIMP-1 measurements would
give a more direct TIMP-1 tumor measurement and thereby
superior results regarding drug sensitivity/resistance. It is
noteworthy that the data obtained in our breast cancer study
originated from tumor tissue TIMP-1 measurements from the
primary tumor (13).
Future studies should be designed to determine clinically
relevant cutpoints of plasma TIMP-1 and further prospectively
validate plasma TIMP-1 measurements in the prediction of
response to chemotherapy in patients with metastatic colorectal
cancer. Future studies should also include measurements of
other potential predictive markers in addition to TIMP-1 to
determine if any other biomarker should be included together
with TIMP-1 in a panel of markers to be used to predict
sensitivity/resistance to chemotherapy in patients with meta-
static colorectal cancer.
Table 4. Multivariate Cox regression analysis of OS
Covariate P HR (95% CI)
Randomized to
FLIRI 0.30 1.4 (0.8-2.4)
FOLFIRI
Gender
Male 0.87 0.9 (0.5-1.6)
Female
Localization
Colon 0.74 0.7 (0.4-1.4)
Rectum
Performance status WHO
0 0.008 2.4 (1.2-4.5)
1 + 2
Adjuvant therapy
No 0.30 1.8 (0.6-5.4)
Yes
Age (y) 0.78 1.00 (0.96-1.03)
TIMP-1 loge <0.0001 3.5 (2.1-5.8)
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